Literature DB >> 16452599

Chronic obstructive pulmonary disease: current burden and future projections.

A D Lopez1, K Shibuya, C Rao, C D Mathers, A L Hansell, L S Held, V Schmid, S Buist.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16452599     DOI： 10.1183/09031936.06.00025805

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  388 in total

1.  Identifying key domains of health-related quality of life for patients with chronic obstructive pulmonary disease: interviews with healthcare professionals.

Authors:  Muirne C S Paap; Christina Bode; Lonneke I M Lenferink; Caroline B Terwee; Job van der Palen
Journal:  Qual Life Res       Date:  2014-11-16       Impact factor: 4.147

2.  COPD in India: Iceberg or volcano?

Authors:  Arvind B Bhome
Journal:  J Thorac Dis       Date:  2012-06-01       Impact factor: 2.895

3.  Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease.

Authors:  M Zhang; Q Li; X-Y Zhang; X Ding; D Zhu; X Zhou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-20       Impact factor: 3.267

4.  Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis.

Authors:  Lei Pan; Yong-Zhong Guo; Bo Zhang; Jun-Hong Yan
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

5.  Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

Authors:  Nathaniel M Hawkins; Zhen Huang; Karen S Pieper; Scott D Solomon; Lars Kober; Eric J Velazquez; Karl Swedberg; Marc A Pfeffer; John J V McMurray; Aldo P Maggioni
Journal:  Eur J Heart Fail       Date:  2009-01-27       Impact factor: 15.534

6.  Exposure to PM10 as a risk factor for the development of nasal obstruction and chronic obstructive pulmonary disease.

Authors:  Lazaros Sichletidis; Dionisios Spyratos; Anastasios Tsiotsios; Anna-Bettina Haidich; Ioannis Ganidis; Dimitrios Michailidis; Georgios Triantafyllou; George Kottakis; Dimitrios Melas
Journal:  Int J Occup Environ Health       Date:  2014 Jan-Mar

7.  Role of Cigarette Smoke-Induced Aggresome Formation in Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis.

Authors:  Ian Tran; Changhoon Ji; Inzer Ni; Taehong Min; Danni Tang; Neeraj Vij
Journal:  Am J Respir Cell Mol Biol       Date:  2015-08       Impact factor: 6.914

8.  Randomized, double-blind, placebo-controlled superiority trial of the Yiqigubiao pill for the treatment of patients with chronic obstructive pulmonary disease at a stable stage.

Authors:  Feng-Sen Li; Yan-Li Zhang; Zheng Li; Dan Xu; Chun-Yan Liao; Huan Ma; Li Gong; Jun Su; Qi Sun; Qian Xu; Zhen Gao; Ling Wang; Jing Jing; Jing Wang; Min Jiang; Ge Tian; Bilal Hasan
Journal:  Exp Ther Med       Date:  2016-09-06       Impact factor: 2.447

9.  Patients' perspective of the impact of COPD on quality of life: a focus group study for patients with COPD.

Authors:  Anan Jarab; Eman Alefishat; Tareq Mukattash; Karem Alzoubi; Sharrel Pinto
Journal:  Int J Clin Pharm       Date:  2018-03-14

Review 10.  Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.

Authors:  Gillian M Keating; Paul L McCormack
Journal:  Drugs       Date:  2007       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.